Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Vivian M. Liu, Megan Othus, Rhonda E. Ries, Jasmine Naru, Era L. Pogosova-Agadjanyan, Frederick R. Appelbaum, Lan W. Beppu, Thomas R. Chauncey, Harry P. Erba, John E. Godwin, Matthew Fitzgibbon, Min Fang, Stanley C. Lee, Anna B. Moseley, Jerald P. Radich, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt

Blood (2024) 144 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2024-198506

Published: 2024

Journal Articles

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Sikander Ailawadhi, Antje Hoering, J Christine Ye, Brea Lipe, Thomas R. Chauncey, Krisstina Gowin, David Calverley, Sarah A. Holstein, Erica L. Campagnaro, Adam Rosenthal, Jack Aiello, Saad Z. Usmani, Vincent Rajkumar, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3381.3.

https://doi.org/10.1182/blood-2024-209626

Published: 2024

Journal Articles

Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Blood (2021) 138 (Supplement 1): 799.

https://doi.org/10.1182/blood-2021-151678

Published: 2021

Journal Articles

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Blood (2021) 138 (Supplement 1): 522.

https://doi.org/10.1182/blood-2021-151246

Published: 2021

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Blood (2019) 134 (Supplement_1): 2691.

https://doi.org/10.1182/blood-2019-124529

Published: 2019

Journal Articles

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Brian Kornblit, MD PhD, Barry Storer, Michael B. Maris, MD, Niels Smedegaard Andersen, MD PhD, Thomas R. Chauncey, MD PhD, Effie W. Petersdorf, MD, Ann Woolfrey, MD, David G. Maloney, MD PhD, Rainer Storb, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 369.

https://doi.org/10.1182/blood-2019-123196

Published: 2019

Journal Articles

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Shakira J. Grant, MBBS, Lindsay M. Hannan, MD MSPH, Jessica L. Brand, PhD, Robert E. Richard, MD PhD, Daniel Y. Wu, MD, Solomon A. Graf, MD, Jonathan Grim, MD PhD, Nicholas Burwick, MD, Thomas R. Chauncey, MD PhD

Blood (2019) 134 (Supplement_1): 5883.

https://doi.org/10.1182/blood-2019-122580

Published: 2019

Journal Articles

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, Heather A. Rasmussen, BS, Pamela S. Becker, MD, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2018-99-115476

Published: 2018

Journal Articles

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Abby Statler, Megan Othus, Harry P. Erba, Thomas R. Chauncey, Jerald P. Radich, Steven Coutre, Anjali Advani, Sucha Nand, Farhad Ravandi, Sudipto Mukherjee, Mikkael A. Sekeres

Blood (2018) 131 (25): 2782–2788.

https://doi.org/10.1182/blood-2018-01-826693

Published: 2018

Includes: Supplemental data

Journal Articles

Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion

Merav Bar, MD, Mary Flowers, MD, Barry E. Storer, PhD, Thomas R. Chauncey, MD PhD, Michael A Pulsipher, MD, Monica S Thakar, MD, Wolfgang Bethge, MD, Rainer F. Storb, MD, David G Maloney, Brenda M. Sandmaier, MD

Blood (2016) 128 (22): 2215.

https://doi.org/10.1182/blood.V128.22.2215.2215

Published: 2016

Journal Articles

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Abby Statler, MPH, MA, Megan Othus, PhD, Harry P. Erba, MD PhD, Thomas R. Chauncey, MD PhD, Jerald P. Radich, MD, Steven E. Coutre, MD, Anjali S. Advani, MD, Sucha Nand, MD, Farhad Ravandi, MD, Sudipto Mukherjee, MD, PhD, M.P.H., Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 4002.

https://doi.org/10.1182/blood.V128.22.4002.4002

Published: 2016

Journal Articles

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Solomon A. Graf, MD, Philip A. Stevenson, MS, Leona A. Holmberg, MD PhD, Brian G. Till, MD, Oliver W. Press, MD PhD, Thomas R. Chauncey, MD PhD, Stephen D. Smith, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, MD, William I. Bensinger, MD, John M. Pagel, MD PhD, David G Maloney, MDPhD, Yi Zhou, MD PhD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3985.

https://doi.org/10.1182/blood.V124.21.3985.3985

Published: 2014

Journal Articles

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

Bart L. Scott, Ted A. Gooley, Mohamed L. Sorror, Andrew R. Rezvani, Michael L. Linenberger, Jonathan Grim, Brenda M. Sandmaier, David Myerson, Thomas R. Chauncey, Rainer Storb, Veronika Buxhofer-Ausch, Jerald P. Radich, Frederick R. Appelbaum, H. Joachim Deeg

Blood (2012) 119 (11): 2657–2664.

https://doi.org/10.1182/blood-2011-08-372904

Published: 2012

Journal Articles

Long-term outcomes after transplantation of HLA-identical related G-CSF–mobilized peripheral blood mononuclear cells versus bone marrow

Marco Mielcarek, Barry Storer, Paul J. Martin, Stephen J. Forman, Robert S. Negrin, Mary E. Flowers, Yoshihiro Inamoto, Thomas R. Chauncey, Rainer Storb, Frederick R. Appelbaum, William I. Bensinger

Blood (2012) 119 (11): 2675–2678.

https://doi.org/10.1182/blood-2011-12-396275

Published: 2012

Journal Articles

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward D. Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard T. Maziarz, Thomas R. Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney

Blood (2009) 113 (14): 3383–3391.

https://doi.org/10.1182/blood-2008-07-170746

Published: 2009

Includes: Supplemental data

Journal Articles

Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Andrew R. Rezvani, Wendy Leisenring, Paul L. Martin, Mary E.D. Flowers, David G. Maloney, Thomas R. Chauncey, Brenda M. Sandmaier, Rainer F. Storb

Blood (2007) 110 (11): 1071.

https://doi.org/10.1182/blood.V110.11.1071.1071

Published: 2007

Journal Articles

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Blood (2007) 110 (7): 2744–2748.

https://doi.org/10.1182/blood-2007-03-078592

Published: 2007

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom’s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.

Larry D. Anderson, Jr., Brenda M. Sandmaier, Michael B. Maris, Dietger Niederwieser, Edward Agura, Richard T. Maziarz, Thomas R. Chauncey, Rainer Storb, David G. Maloney

Blood (2006) 108 (11): 3034.

https://doi.org/10.1182/blood.V108.11.3034.3034

Published: 2006

NARROW

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

Long-term outcomes after transplantation of HLA-identical related G-CSF–mobilized peripheral blood mononuclear cells versus bone marrow

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom’s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only